Ivabradine Tablet, Film Coated
Product Images NDC 72603-935

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 72603-935). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ivabradine-5mg-60s-cntr (Ivabradine 5mg 60s Cntr)

This is information about Ivabradine Tablets, a medication containing 5 mg of ivabradine hydrochloride per film-coated tablet. The usual dose information can be found in the package insert. The medication should be stored at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). Produced for Northstar Rx LLC in Tennessee, USA, this product is from India. The tablets are provided in a pack of 60 and come with a Medication Guide for each patient. Remember to keep this medication out of the sight and reach of children.*

FDA Label Image

Ivabradine-7-5mg-60s-cntr (Ivabradine 7 5mg 60s Cntr)

This is a description of Ivabradine Tablets, a medication containing 7.5 mg ivabradine per film-coated tablet, equivalent to 8.085 mg ivabradine as hydrochloride. These tablets are usually prescribed individually to patients. The package includes 60 film-coated tablets to be stored at 25°C (77°F) with allowable temperature variations of 15-30°C (59-86°F). The manufacturer is Northstar Rx LLC in Memphis, TN, and the tablets are produced by MSN Laboratories Private Limited in Telangana, India. The medication is a product of India and the manufacture date is marked as 03/2026.*

FDA Label Image

Ivabradine-figure-1 (Ivabradine Figure 1)

FDA Label Image

Ivabradine-figure-2 (Ivabradine Figure 2)

This text provides information about potential drug interactions involving strong CYP3A4 inhibitors (ketoconazole, diltiazem, verapamil, grapefruit juice) and a CYP1A1 inducer (St. John's wort). It also lists various other medications (e.g. shenan, lacidipine, simvastatin, lansoprazole, omeprazole, warfarin) with recommendations for dose adjustments. PK measures are mentioned along with a recommendation to avoid use in some cases and no dose adjustments in others.*

FDA Label Image

Ivabradine-figure-3 (Ivabradine Figure 3)

This text provides a table with information on the number of subjects at risk for placebo and Ivabradine groups, as well as data on the time from randomization in months. It appears to be related to a study or clinical trial.*

FDA Label Image

Ivabradine-figure-4 (Ivabradine Figure 4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.